Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722046 · ClinicalTrials.gov registry record · Phase 2
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
NCT00722046 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 198 participants.
The verdict
NCT00722046, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
Study Summary
Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.
Interventions
- DRUG Placebo
- BIOLOGICAL PF-04360365 0.1 mg/kg
- BIOLOGICAL PF-04360365 0.5 mg/kg
- BIOLOGICAL PF-04360365 1 mg/kg
- BIOLOGICAL PF-04360365 3 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2008-12-05 |
| Est. Completion | 2011-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722046
The ClinicalTrials.gov registry entry for NCT00722046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00722046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722046 about?
NCT00722046 is a clinical study titled "Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease". Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.
What is the current status of trial NCT00722046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2008-12-05. Estimated completion is 2011-08-16.
What interventions are being tested in trial NCT00722046?
The interventions under investigation include: Placebo (DRUG), PF-04360365 0.1 mg/kg (BIOLOGICAL), PF-04360365 0.5 mg/kg (BIOLOGICAL), PF-04360365 1 mg/kg (BIOLOGICAL), PF-04360365 3 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00722046?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.